US Patent

US7850990 — Compositions for delivery of drug combinations

Method of Use · Assigned to Celator Pharmaceuticals Inc · Expires 2027-01-23 · 1y remaining

Vulnerability score 63/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions that deliver non-antagonistic combinations of two or more agents, such as antineoplastic agents, like Cytarabine.

USPTO Abstract

Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.

Drugs covered by this patent

Cytarabine (Cytarabine) · Nippon Shinyaku Co., Ltd.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3147`	—	Cytarabine

Patent Metadata

Patent number: US7850990
Jurisdiction: US
Classification: Method of Use
Expires: 2027-01-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Celator Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.